GlassScriptPhysician profile
Mark N Jabro
NPI 1326058330
$58,946.01
in general payments reported to CMS, 2019-2025
9 companies · $35K in 2025
The $35K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,241 · 2020: $1,836 · 2021: $758 · 2022: $443 · 2023: $291 · 2024: $15K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Consulting Fee: $14K · Travel and Lodging: $7,867 · Food and Beverage: $2,585 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,500.00 |
| Consulting Fee | $13,600.00 |
| Travel and Lodging | $7,867.29 |
| Food and Beverage | $2,585.31 |
| Education | $114.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $42,379.66 | 2022-2025 | Zepbound, Mounjaro, Kisunla |
| Novo Nordisk INC | $6,648.06 | 2019-2025 | Wegovy, Saxenda |
| Eli Lilly and Company | $5,503.67 | 2024 | Zepbound |
| Vivus LLC | $3,408.69 | 2020-2024 | Qsymia |
| Rhythm Pharmaceuticals, INC. | $395.05 | 2022-2024 | Imcivree, Imcivree |
| Currax Pharmaceuticals LLC | $334.42 | 2021-2023 | Nexletol, Contrave, Nexlizet |
| Intra-Sana Laboratories | $206.68 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Viiv Healthcare Company | $35.35 | 2020 | |
| Supernus Pharmaceuticals, INC. | $34.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jabro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.